Gefapixant

Unassigned

New Medicines

Chronic cough, including cough with Idiopathic Pulmonary Fibrosis

Information

New molecular entity
Merck Sharp & Dohme (MSD)
Merck & Co (name used in US for MSD)

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Purinergic P2X3 receptor antagonist; P2X3 receptors are expressed in afferent neurones that transmit pain perception.
Chronic cough, most commonly defined as cough lasting 3 months or more, is common; a reasonably robust estimate suggests that global prevalence is about 9.6% and European prevalence about 12.7% [2]. There are no effective drug treatments with an acceptable therapeutic ratio [3].
Chronic cough, including cough with Idiopathic Pulmonary Fibrosis
Oral

Further information

Yes
To be confirmed

Evidence based evaluations